Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA7 | P43166 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13431154 | 0.86 | PKM (0.37) | HSP90AB1CA1CA2CA7PKM | |
| SCHEMBL1062911 | 0.79 | CA1 (0.48) | HSP90AB1ABCB1CA1CA2CA7 | |
| SCHEMBL11112327 | 0.77 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL14294524 | 0.77 | PKM (0.33) | HSP90AB1CA1CA2CA7PKM | |
| SCHEMBL13431148 | 0.77 | CA1 (0.46) | HSP90AB1CA1CA2CA7PKM | |
| SCHEMBL23141786 | 0.76 | ALDH1A1 (0.41) | HSP90AB1ABCB1MEN1KMT2AALDH1A1 | |
| SCHEMBL27602042 | 0.74 | ABCB1 (0.31) | HSP90AB1ABCB1CA1CA2CA7 | |
| SCHEMBL12566085 | 0.73 | ABCB1 (0.48) | HSP90AB1ABCB1PKMMEN1KMT2A | |
| SCHEMBL12640263 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL4956793 | 0.71 | HSP90AB1 (0.48) | HSP90AB1ABCB1MEN1KMT2AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359349-B2 | Substituted quinazolines as kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150141442-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | Intellikine, LLC. (US) | 2014-11-27 | — | — | US | disclosed |
| EP-2139484-B1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-6965030-B2 | 6-alkoxy-pyrido-pyridine | ROCHE PALO ALTO LLC (US) | 2005-11-15 | — | — | US | disclosed |
| US-20040038999-A1 | 6-alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC | 2004-02-26 | — | — | US | disclosed |
| EP-1123295-A1 | BICYCLIC NITROGEN HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000024744-A1 | BICYCLIC NITROGEN HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3CB, PIK3C3 | HSP90AB1 819/4885ABCB1 738/4885CA1 3349/4885 |
| US-20150141442-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3CB, PIK3C3 | HSP90AB1 819/4885ABCB1 738/4885CA1 3349/4885 |
| US-20040038999-A1 | 6-alkoxy-pyrido-pyrimidines | CYP2B6, CYP2D6, CNR1 | HSP90AB1 4646/4885ABCB1 176/4885CA1 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.